Biosyent Inc. · TSXV:RX
Biosyent — Q2 2022 Earnings Presentation
15 slides from Biosyent's earnings presentation, Aug 23, 2022
Slide 1: BioSyent Inc. Q2 / H1 2022 Results
BioSyent Inc. Q2 / H1 2022 Results AUGUST 23, 2022 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Sales, EBITDA and NIAT - Q2 2022
Sales, EBITDA and NIAT Quarter (Q2) ended June 30, 2022 +53% 7,000 -9% Q2 2022 Sales: 6,000 +35% -6%* Canadian Pharma -100% International Pharma 5,000 -7% -20% Legacy 4,000 *+1% on Continuing Canadian Pharma Brands (excluding brands CAD (000's) discontinued in Jan 2022) 3,000 2,000 +40% +13% +66% 48
Slide 4: Sales, EBITDA and NIAT - H1 2022
Sales, EBITDA and NIAT First Half (H1) ended June 30, 2022 +36% 14,000 -7% H1 2022 Sales: 12,000 +12% +35% -2%* Canadian Pharma -57% International Pharma 10,000 +3% Legacy 8,000 *+4% on Continuing Canadian CAD (000's) Pharma Brands (excluding brands discontinued in Jan 2022) 6,000 +26% +2% 4,000 +48
Slide 5: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS Q2 2022 $1,217,883 $0.10 Q1 2022 $1,587,904 $0.13 $0.50 Q4 2021 $1,877,804 $0.15 Q3 2021 $1,721,320 $0.13 Q2 2021 $1,018,074 $0.08 Q1 2021 $1,664,368 $0.13 $0.33 Q4 2020 $665,702 $0.05 Q3 2020 $955,909 $0.07 5 | www.biosyent.com | TSXV: RX
Slide 6: Q2 / H1 2022 Sales Summary
Q2 / H1 2022 Sales Summary Q2 ‘22 Q2 ‘22 vs. H1 ‘22 H1 ‘22 vs. Sales ($) Q2 ’21 (%) Sales ($) H1 ’21 (%) Canadian Pharma ($) $6,272k (6%) $12,591k (2%) FeraMAX® wholesale trade FeraMAX® (units) (8%) (2%) inventory slightly reduced in Q2 – retail sales showed RepaGyn® (units) +13% +14% modest growth
Slide 7: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 7 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 8: A New Platform for FeraMAX Product Innovation
A New Platform for FeraMAX® Product Innovation FeraMAX® Pd platform introduced in October 2020 Patented delivery system based on Polydextrose Iron Complex (“PDIC”) Foundation for future product developments FeraMAX® Pd Therapeutic 150 launched Nov 2020 FeraMAX® Pd Powder 15 launched Oct 20
Slide 9: Growth Drivers
Growth Drivers Investments In: FeraMAX® Pd Platform – Life Cycle Strategy • New product early 2023 Field Salesforce • Additional products in development HRT agent for menopause therapy • Launched July 2020 Marketing Resources First formulation combining acetaminophen + ibuprofen for pain relief in C
Slide 10: Cash Balance & Return on Equity (RoE)
Cash Balance & Return and Equity (“RoE”) • Zero Debt 30,000 25% 21% • Jun 30/22 Working Capital of 28,000 20% 20% $31.0M 27,899 16% 26,000 • TTM Jun 30/22 Cash from 15% Operations = $6.1M 24,000 24,813 CAD (000's) • TTM Jun 30/22 RoE Net of RoE % 10% Cash and ST investments = 22,000 145% 21,468 5% 2
Slide 11: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $27.9M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders 11 | www.biosyent.com | TSXV: RX
Slide 12: Normal Course Issuer Bid (NCIB)
Normal Course Issuer Bid (NCIB) Fully Diluted No. Shares Shares Period Repurchased Outstanding Dec 10, 2018 14,675,307 315,300 shares NCIB Purchases: Dec 10, 2018 – present (2,091,225) purchased Jan 1 – Aug 19, As of August 19, 2022 12,619,042 2022 14% reduction in f/d shares since commencing NCIB
Slide 13: Stock Information
Stock Information As at August 19, 2022 Exchange & Trading Symbol 0% TSXV: RX August 19, 2022 Closing Stock Price (CAD) $7.99 52 Week Hi/Low: $10.00 / $6.76 Issued Common Shares: 12,448,561 Treasury – RSU Shares in Trust (235,450) Outstanding Common Shares: 12,213,111 Options Outstanding 164,475 RSU
Slide 14: Profitable. Well Positioned. Growth Assets.
PROFITABLE. WELL POSITIONED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 14 | www.biosyent.com | TSXV: RX
Slide 15: Thank You
THANK YOU 2476 Argentia Road, Suite 402 +1 905 206 0013 [email protected] www.biosyent.com Mississauga ON L5N 6M1 Canada 15 | www.biosyent.com | TSXV: RX